Patents by Inventor Matthias Frech

Matthias Frech has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Specific mechanism for inhibiting platelet adhesion to collagen
    Patent number: 7459438
    Abstract: The present invention relates to the polypeptide Saratin and its use for the manufacture of a medicament having the capability to significantly decrease platelet adhesion and platelet accumulation after vascular injuries or endarterectomy. The invention furthermore relates to a novel medical use of Saratin as an inhibitor of thrombosis and intimal hyperplasia, where the Saratin polypeptide may be used locally as a topical agent or as a coating on, or otherwise incorporated or associated with medical devices or vascular grafts.
    Type: Grant
    Filed: December 21, 2004
    Date of Patent: December 2, 2008
    Assignee: Merck Patent GmbH
    Inventors: Christopher Barnes, Matthias Frech, Uwe Hofmann, Johannes Gleitz, Wolfgang Strittmatter
  • Dihydrobenzothiophenes
    Publication number: 20070219246
    Abstract: Compounds of the formula (I) in which W, R1, R2, R3, R4, and q have the meanings indicated in Claim 1, can be employed, inter alia, for the treatment of tumours.
    Type: Application
    Filed: April 28, 2005
    Publication date: September 20, 2007
    Inventors: Dirk Finsinger, Soheila Anzali, Matthias Frech, Johannes Gleitz, Nina Heiss, Bjoern Hock, Kai Schiemann, Frank Zenke
  • Specific mechanism for inhibiting platelet adhesion to collagen
    Publication number: 20050143305
    Abstract: Use of the polypeptide Saratin for the manufacture of a medicament having the capability to significantly decrease platelet adhesion and platelet accumulation after vascular injuries or endarterectomy. The invention furthermore relates to a novel medical use of Saratin as an inhibitor of thrombosis and intimal hyperplasia, wherein said polypeptide may be used locally as a topical agent or as a coating on, or otherwise incorporated or associated with medical devices.
    Type: Application
    Filed: December 21, 2004
    Publication date: June 30, 2005
    Inventors: Christopher Barnes, Matthias Frech, Uwe Hofmann, Johannes Gleitz, Wolfgang Strittmatter
  • Saratin for inhibiting platelet adhesion to collagen
    Patent number: 6881722
    Abstract: Use of the polypeptide Saratin for the manufacture of a medicament having the capability to significantly decrease platelet adhesion and platelet accumulation after vascular injuries or endarterectomy. The invention furthermore relates to a novel medical use of Saratin as an inhibitor of thrombosis and intimal hyperplasia, wherein the Saratin polypeptide may be used locally as a topical agent or as a coating on, or otherwise incorporated or associated with medical devices.
    Type: Grant
    Filed: August 23, 2001
    Date of Patent: April 19, 2005
    Assignee: Merck GmbH
    Inventors: Christopher Barnes, Matthias Frech, Uwe Hofmann, Johannes Gleitz, Wolfgang Strittmatter
  • Saratin for inhibiting platelet adhesion to collagen
    Publication number: 20030190342
    Abstract: Use of the polypeptide Saratin for the manufacture of a medicament having the capability to significantly decrease platelet adhesion and platelet accumulation after vascular injuries or endarterectomy. The invention furthermore relates to a novel medical use of Sara tin as an inhibitor of thrombosis and intimal hyperplasia, wherein said polypeptide may be used locally as a topical agent or as a coating on, or otherwise incorporated or associated with medical devices.
    Type: Application
    Filed: February 24, 2003
    Publication date: October 9, 2003
    Inventors: Christopher Barnes, Matthias Frech, Uwe Hofmann, Johannes Gleitz, Wolfgang Strittmatter
  • Screening method
    Patent number: 6054285
    Abstract: The invention concerns a method for screening a compound which is a candidate modulator of signal response comprising the steps of; (a) incubating the compound with the PH domain of a signaling molecule which is capable of fluorescing; (b) determining the phospholipid-induced modulation in florescence of the PH domain, an alteration of the florescence in the presence of the compound being indicative of a functional interaction between the compound and the PH domain.
    Type: Grant
    Filed: June 10, 1998
    Date of Patent: April 25, 2000
    Assignee: Novartis AG
    Inventors: Brian Arthur Hemmings, Matthias Frech